Free Newsletter
SPOTLIGHT: Barr, Novartis in Ritalin LA patent fight
Free newsletter via e-mail
Tools
Barr Pharmaceuticals is challenging Novartis' patent on the attention deficit hyperactivity drug Ritalin LA, which sold $109 million worth in the U.S. for the year ending in August. The Swiss drug maker filed suit against Barr Friday, hoping to keep the generics firm from taking its version of the product to market. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: